Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

PARP inhibition in the treatment of prostate cancer

23 Jul 2021

United Kingdom of Great Britain and Northern Ireland

Part 6: Which different PARP inhibitors are available

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 6: Which different PARP inhibitors are available ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 7: Similarities and Differences

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 7: Similarities and Differences ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 8: How PARP inhibitors are being used now

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 8: How PARP inhibitors are being used now ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 9: What PARP inhibitors mean for the future and what to look out for

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 9: What PARP inhibitors mean for the future and what to look out for ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 1: When to test

PARP inhibition in the treatment of prostate cancer

Part 1: When to test ( PARP inhibition in the treatment of prostate cancer )

Part 2: Who to test

PARP inhibition in the treatment of prostate cancer

Part 2: Who to test ( PARP inhibition in the treatment of prostate cancer )

Part 3: How to test

PARP inhibition in the treatment of prostate cancer

Part 3: How to test ( PARP inhibition in the treatment of prostate cancer )

Part 4: Metastatic prostate cancer and HRR defects

PARP inhibition in the treatment of prostate cancer

Part 4: Metastatic prostate cancer and HRR defects ( PARP inhibition in the treatment of prostate cancer )

Part 5: BRCA 1/2 mutations and prostate cancer

PARP inhibition in the treatment of prostate cancer

Part 5: BRCA 1/2 mutations and prostate cancer ( PARP inhibition in the treatment of prostate cancer )

More from ecancer